Zostavax

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prevention of : Herpes-Zoster

Conditions

Prevention of : Herpes-Zoster

Trial Timeline

Oct 26, 2007 โ†’ Jun 3, 2009

About Zostavax

Zostavax is a phase 3 stage product being developed by Merck for Prevention of : Herpes-Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT00561080. Target conditions include Prevention of : Herpes-Zoster.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT01391546Phase 3Completed
NCT01328548Pre-clinicalCompleted
NCT00561080Phase 3Completed

Competing Products

20 competing products in Prevention of : Herpes-Zoster

See all competitors